Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab versus placebo in allergic fungal rhinosinusitis (AFRS)
2020-002999-12Phase 3
- Sponsor
- Sanofi
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic fungal rhinosinusitis (AFRS) comparing Dupilumab with Placebo (2 arms).
02
Drugs
03
Conditions
allergic fungal rhinosinusitis (AFRS)
Beyond the preview
Go deeper on 2020-002999-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002999-12.